Maria Ijaz
Maria Ijaz has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Abdullah
Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA
1 shared publication - Muhammad Saad Anwar
Internal Medicine, Monmouth Medical Center, Long Branch, USA
1 shared publication - Muhammad Sikandar Karim
Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA
1 shared publication - Raquel Rosen
Nephrology, Bassett Medical Center, Cooperstown, USA
1 shared publication - Syed Rizwan Ali Bokhari
Tulane Univ, Sch Med, Nephrol, 1430 Tulane Ave, New Orleans, LA 70112 USA
1 shared publication
Latest Publications
- Open Access
- 15 December 2022
- Published by Springer Nature in Cureus
- Vol. 14 (12) , e32603
Anti-neutrophil Cytoplasmic Antibody-Associated Glomerulonephritis Secondary to Hydralazine: A Case Report
Hydralazine is a vasodilator used in the treatment of resistant hypertension. It is a safe and widely used antihypertensive medicine. Its common adverse effects include headache, rebound tachycardia, fluid retention, and angina. It is a rare cause of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) with pulmonary and renal involvement. We report a case of a 74-year-old woman, with over eight years of use of hydralazine, who presented to the hospital with shortness of breath and cough. Blood work revealed deranged renal function with high creatinine levels. Serology workup was positive for anti-histone antibodies (AHA), anti-nuclear antibodies (ANA), myeloperoxidase (MPO) ANCA and proteinase-3 (PR-3) ANCA. Renal biopsy showed diffusely flattened tubular epithelium, focal micro vesicular degeneration, and focal loss of the brush border of the proximal tubular epithelium. Hydralazine was stopped and the patient was treated with corticosteroids, resulting in the resolution of her kidney injury.
- 15 December 2022
- Published by Springer Nature in Cureus
- Vol. 14 (12) , e32603
Open AccessAnti-neutrophil Cytoplasmic Antibody-Associated Glomerulonephritis Secondary to Hydralazine: A Case Report
Hydralazine is a vasodilator used in the treatment of resistant hypertension. It is a safe and widely used antihypertensive medicine. Its common adverse effects include headache, rebound tachycardia, fluid retention, and angina. It is a rare cause of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) with pulmonary and renal involvement. We report a case of a 74-year-old woman, with over eight years of use of hydralazine, who presented to the hospital with shortness of breath and cough. Blood work revealed deranged renal function with high creatinine levels. Serology workup was positive for anti-histone antibodies (AHA), anti-nuclear antibodies (ANA), myeloperoxidase (MPO) ANCA and proteinase-3 (PR-3) ANCA. Renal biopsy showed diffusely flattened tubular epithelium, focal micro vesicular degeneration, and focal loss of the brush border of the proximal tubular epithelium. Hydralazine was stopped and the patient was treated with corticosteroids, resulting in the resolution of her kidney injury.